Nanotechnology applied to the treatment of malaria

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 560-575

  Santos Magalhães, Nereide Stela ^a   Mosqueira, Vanessa Carla Furtado ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Antimalarials; Liposomes; Malaria; Nanocapsules; Nanocarriers; Nanoparticles

Indexed keywords

ADVANCED TECHNOLOGY; ANIMAL MODEL; ANTIMALARIALS; DELIVERY SYSTEMS; HIGH DOSE; INFECTED CELLS; INFECTIOUS DISEASE; INTRACELLULAR PARASITES; MALARIA; MALARIA PARASITE; MULTIPLE DRUG RESISTANCE; NANO-SIZED; NANOCARRIERS; SIDE EFFECT; SOLID LIPID NANOPARTICLES;

BIOCHEMISTRY; CHEMOTHERAPY; DRUG INTERACTIONS; INNOVATION; LIPOSOMES; MICROEMULSIONS; NANOCAPSULES; NANOPARTICLES; NANOTECHNOLOGY; PHOSPHOLIPIDS; SPECIAL EFFECTS; TECHNOLOGICAL FORECASTING;

DRUG DOSAGE;

AMODIAQUINE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE; BIGUANIDE DERIVATIVE; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; DENDRIMER; DIHYDROARTEMISININ; FANSIDAR; HALOFANTRINE; HYDROXYCHLOROQUINE; LIPOSOME; MALOPRIM; MEFLOQUINE; NANOCAPSULE; NANOCARRIER; NANOSPHERE; POLYMER; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE SULFATE; SOLID LIPID NANOPARTICLE; TAFENOQUINE;

AGRANULOCYTOSIS; ALLERGIC REACTION; ANEMIA; BRAIN BLOOD FLOW; BRAIN MALARIA; CINCHONISM; CYTOLYSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FEVER; HEADACHE; HEART ARRHYTHMIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPOGLYCEMIA; MACULAR RETINOPATHY; MALARIA; MENTAL DISEASE; METHEMOGLOBINEMIA; MICROEMULSION; MORBIDITY; MORTALITY; MYALGIA; NANOEMULSION; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMERIZATION; PRIORITY JOURNAL; QT PROLONGATION; RETINOPATHY; REVIEW; SPLENOMEGALY; SYMPTOMATOLOGY;

ANIMALS; ANTIMALARIALS; DENDRIMERS; DEVELOPING COUNTRIES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; MALARIA; MALARIA VACCINES; NANOPARTICLES; NANOTECHNOLOGY; SUSPENSIONS;

EID: 76849088745     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.024     Document Type: Review

References (151)

1. WHO, World Malaria Report (2008), http://www.who.int/malaria/wmr2008/malaria2008.pdf, accessed on 15th April 2009.
2. Gardella F., Assi S., Simon F., Bogreau H., Eggelte T., Ba F., Foumane V., Henry M.C., Kientega P.T., Basco L., Trape J.F., Lalou R., Martelloni M., Desbordes M., Baragatti M., Briolant S., Almeras L., Pradines B., Fusai T., and Rogier C. Antimalarial drug use in general populations of tropical Africa. Malaria J. 7 (2008)
3. WHO, The Africa Malaria Report (2003), http://www.rollbackmalaria.org/amd2003/amr2003/pdf/amr2003.pdf, accessed on 15th June 2009.
4. Rathore D., McCutchan T.F., Sullivan M., and Kumar S. Antimalarial drugs: current status and new developments. Expert Opin. Invest. Drugs 14 (2005) 871-883
5. Smith L.A., Jones C., Meek S., and Webster J. Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works?. Am. J. Trop. Med. Hyg. 80 (2009) 326-335
6. WHO, Global Malaria Control and Elimination (2008), http://apps.who.int/malaria/docs/elimination/MalariaControlEliminationMeeting.pdf, accessed on 30th June 2009.
7. Winstanley P., and Ward S. Malaria chemotherapy. Adv. Parasitol. 61 (2006) 47-76
8. Krettli A.U., Andrade-Neto V.F., Brandão M.G.L., and Ferrari W.M.S. The search for new antimalarial drugs from plants used to treat fever and malaria or plants randomly selected: A review. Mem. I. Oswaldo Cruz 96 (2001) 1033-1042
9. Greenwood B.M., Fidock D.A., Kyle D.E., Kappe S.H.I., Alonso P.L., Collins F.H., and Duffy P.E. Malaria: Progress, perils, and prospects for eradication. J. Clin. Invest. 118 (2008) 1266-1276
10. Krettli A.U., Adebayo J.O., and Krettli L.G. Testing of natural products and synthetic molecules aiming at new antimalarials. Curr. Drug Targets 10 (2009) 261-270
11. Skinner-Adams T.S., McCarthy J.S., Gardiner D.L., and Andrews K.T. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol. 24 (2008) 264-271
12. Whitworth J., Morgan D., Quigley M., Smith A., Mayanja B., Eotu H., Omoding N., Okongo M., Malamba S., and Ojwiya A. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: A cohort study. Lancet 356 (2000) 1051-1056
13. Greenberg A.E., Nsa W., Ryder R.W., Medi M., Nzeza M., Kitadi N., Baangi M., Malanda N., Davachi F., and Hassig S.E. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire - a prospective, longitudinal cohort study of 587 children. New Engl. J. Med. 325 (1991) 105-109
14. Grimwade K., French N., Mbatha D.D., Zungu D.D., Dedicoat M., and Gilks C.F. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr. Infect. Dis. J. 22 (2003) 1057-1063
15. Breman J.G., and Plowe C.V. A malaria vaccine for control: more progress. J. Infect. Dis. 200 (2009) 317-320
16. Kester K.E., Cummings J.F., O. O.A., Ockenhouse C.F., Krzych U., Moris P., Schwenk R., Nielsen R.A., Debebe Z., Pinelis E., Juompan L., Williams J., Dowler M., Stewart V.A., Wirtz R.A., Dubois M.C., Lievens M., Cohen J., Ballou W.R., and Heppner D.G.J. S.V.E.G. RTS, randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200 (2009) 337-346
17. Mettens P., Dubois P.M., Demoitié M.A., Bayat B., Donner M.N., Bourguignon P., Stewart V.A., Heppner Jr. D.G., Garçon N., and Cohen J. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen. Vaccine 26 (2008) 1072-1082
18. Bacon D.J., Jambou R., Fandeur T., Le Bras J., Wongsrichanalai C., Fukuda M.M., Ringwald P., Sibley C.H., and Kyle D.E. World antimalarial resistance network (WARN) II: In vitro antimalarial drug susceptibility. Malaria J. 6 (2007) 1-8
19. Barratt G.M. Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today 3 (2000) 163-171
20. Vauthier C., and Couvreur P. Nanomedicines: a new approach for the treatment of serious diseases. J. Biomed. Nanotechnol. 3 (2007) 223-234
21. Forrest M.L., and Kwon G.S. Clinical developments in drug delivery nanotechnology. Adv. Drug Deliv. Rev. 60 (2008) 861-862
22. Sharma M.K., Rao V.K., Agarwal G.S., Rai G.P., Gopalan N., Prakash S., Sharma S.K., and Vijayaraghavan R. Highly sensitive amperometric immunosensor for detection of Plasmodium falciparum histidine-rich protein 2 in serum of humans with malaria: comparison with a commercial kit. J. Clin. Microbiol. 46 (2008) 3759-3765
23. Wiwanitkit V. Alternative tools for field analysis on malarial infection: a reappraisal. Clin. Ther. 160 (2009) 83-85
24. Kayser O., and Kiderlen A.F. Delivery strategies for antiparasitics. Expert Opin. Invest. Drugs 12 (2003) 197-207
25. Date A.A., Joshi M.D., and Patravale V.B. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 505-521
26. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 (2002) 856-864
27. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner Jr. D.G., Hall T., Wellde B.T., White K., Sun P., Schwenk R., Krzych U., Delchambre M., Voss G., Dubois M.C., Gasser Jr. R.A., Dowler M.G., O'Brien M., Wittes J., Wirtz R., Cohen J., and Ballou W.R. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS, S/AS02A in malaria-naive adults. Vaccine 25 (2007) 5359-5366
28. Combadière B., and Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 31 (2008) 293-315
29. Peek L.J., Middaugh C.R., and Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 (2008) 915-928
30. Newton P.N., Ward S., Angus B.J., Chierakul W., Dondorp A., Ruangveerayuth R., Silamut K., Teerapong P., Suputtamongkol Y., Looareesuwan S., and White N.J. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 184-186
31. Trouet A., Pirson P., and Steiger R. Development of new derivatives of primaquine by association with lysosomotropic carriers. Bull. World Health Organ. 59 (1981) 449-458
32. Mosqueira V.C.F., Loiseau P.M., Bories C., Legrand P., Devissaguet J.P., and Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother. 48 (2004) 1222-1228
33. Leite E.A., Grabe-Guimarães A., Guimarães H.N., Machado-Coelho G.L.L., Barratt G., and Mosqueira V.C.F. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci. 80 (2007) 1327-1334
34. Carcaboso A.M., Hernández R.M., Igartua M., Gascón A.R., Rosas J.E., Patarroyo M.E., and Pedraz J.L. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int. J. Pharm. 260 (2003) 273-282
35. Krettli A.U., and Miller L.H. Malaria: A sporozoite runs through it. Curr. Biol. 11 (2001) R409-R412
36. WHO, Guidelines for the Treatment of Malaria (2006), http://www.whqlibdoc.who.int/publications/2006/9241546948_eng.pdf, accessed on 20th March 2009.
37. Mohanty S., Patel D.K., Pati S.S., and Mishra S.K. Adjuvant therapy in cerebral malaria. Ind. J. Med. Res. 124 (2006) 245-260
38. Coltel N., Combes V., Hunt N.H., and Grau G.E. Cerebral malaria - a neurovascular pathology with many riddles still to be solved. Curr. Neurovasc. Res. 1 (2004) 91-110
39. Pouvelle B., Matarazzo V., Jurzynski C., Nemeth J., Ramharter M., Rougon G., and Gysin J. Neural cell adhesion molecule, a new cytoadhesion receptor for Plasmodium falciparum-infected erythrocytes capable of aggregation. Infect. Immun. 75 (2007) 3516-3522
40. Whitty C.J.M., and Sanderson F. New therapies and changing patterns of treatment for malaria. Curr. Opin. Infect. Dis. 12 (1999) 579-584
41. WHO, Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring (2005), www.who.int/malaria/rbm/Attachment/20041108/SusceptibilityPlasmodium_report.pdf, accessed on 25th March 2009.
42. Price R.N., Dorsey G., Ashley E.A., Barnes K.I., Baird J.K., d'Alessandro U., Guerin P.J., Laufer M.K., Naidoo I., Nosten F., Olliaro P., Plowe C.V., Ringwald P., Sibley C.H., Stepniewska K., and White N.J. World antimalarial resistance network I: Clinical efficacy of antimalarial drugs. Malaria J. 6 (2007) 1-9
43. Becker K., and Kirk K. Of malaria, metabolism and membrane transport. Trends Parasitol. 20 (2004) 590-596
44. Valderramos S.G., and Fidock D.A. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 27 (2006) 594-601
45. Fidock D.A., Eastman R.T., Ward S.A., and Meshnick S.R. Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol. 24 (2008) 537-544
46. Vale N., Moreira R., and Gomes P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44 (2009) 937-953
47. Crockett M., and Kain K.C. Tafenoquine: a promising new antimalarial agent. Expert Opin. Investig. Drugs 16 (2007) 705-715
48. Biagini G.A., Ward S.A., and Bray P.G. Malaria parasite transporters as a drug-delivery strategy. Trends Parasitol. 21 (2005) 299-301
49. + leak from the digestive vacuole in chloroquine-resistant malaria parasites. J. Cell Sci. 121 (2008) 1624-1632
50. Bareford L.M., and Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007) 748-758
51. Ho L.W., Bendayan R., Rauth A.M., Hui Y.X., Babakhanian K., and Xiao Y.W. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 317 (2006) 1372-1381
52. Qiu L., Jing N., and Jin Y. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int. J. Pharm. 361 (2008) 56-63
53. Newton C.R.J.C., and Krishna S. Severe falciparum malaria in children: Current understanding of pathophysiology and supportive treatment. Pharmacol. Ther. 79 (1998) 1-53
54. Mishra S.K., and Newton C.R. Diagnosis and management of the neurological complications of falciparum malaria. Nat. Rev. Neurol. 5 (2009) 189-198
55. Krishna S., Bustamante L., Haynes R.K., and Staines H.M. Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 29 (2008) 520-527
56. Pouvelle B., Spiegel R., Hsiao L., Howard R.J., Morris R.L., Thomas A.P., and Taraschi T.F. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 353 (1991) 73-75
57. Goodyer I.D., Pouvelle B., Schneider T.G., Trelka D.P., and Taraschi T.F. Characterization of macromolecular transport pathways in malaria-infected erythrocytes. Mol. Biochem. Parasitol. 87 (1997) 13-28
58. Charpian S., and Przyborski J.M. Protein transport across the parasitophorous vacuole of Plasmodium falciparum: Into the great wide open. Traffic 9 (2008) 157-165
59. Vial H.J., Wein S., Farenc C., Kocken C., Nicolas O., Ancelin M.L., Bressolle F., Thomas A., and Calas M. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15458-15463
60. Richier E., Biagini G.A., Wein S., Boudou F., Bray P.G., Ward S.A., Precigout E., Calas M., Dubremetz J.F., and Vial H.J. Potent antihematozoan activity of novel bisthiazolium drug T16: Evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp. Antimicrob. Agents Chemother. 50 (2006) 3381-3388
61. Gornicki P. Apicoplast fatty acid biosynthesis as a target for medical intervention in Apicomplexan parasites. Int. J. Parasitol. 33 (2003) 885-896
62. Biagini G.A., Pasini E.M., Hughes R., De Koning H.P., Vial H.J., O'Neill P.M., Ward S.A., and Bray P.G. Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs. Blood 104 (2004) 3372-3377
63. Barratt G. Colloidal drug carriers: Achievements and perspectives. Cell. Mol. Life Sci. 60 (2003) 21-37
64. Devalapally H., Chakilam A., and Amiji M.M. Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci. 96 (2007) 2547-2565
65. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., and Ning J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Deliv. Rev. 60 (2008) 939-954
66. Owens Iii D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
67. Legrand P., Mosqueira V., Loiseau P., Bories C., and Barratt G. Long circulating nanocapsules: Interest in the treatment of severe malaria with halofantrine. Ann. Pharm. Fr. 61 (2003) 196-202
68. Chimanuka B., Gabriëls M., Detaevernier M.R., and Plaizier-Vercammen J.A. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J. Pharm. Biomed. 28 (2002) 13-22
69. Longmuir K.J., Robertson R.T., Haynes S.M., Baratta J.L., and Waring A.J. Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence. Pharm. Res. 23 (2006) 759-769
70. Owais M., Varshney G.C., Choudhury A., Chandra S., and Gupta C.M. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob. Agents Chemother. 39 (1995) 180-184
71. Gupta Y., Jain A., and Jain S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59 (2007) 935-940
72. Föger F., Noonpakdee W., Loretz B., Joojuntr S., Salvenmoser W., Thaler M., and Bernkop-Schnürch A. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. Int. J. Pharm. 319 (2006) 139-146
73. Haas S.E., Bettoni C.C., de Oliveira L.K., Guterres S.S., and Dalla Costa T. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int. J. Antimicrob. Agents 34 (2009) 156-161
74. Lasic D.D., Martin F.J., and Mayhew E. Stealth liposomes. Ann. Biomed. Eng. 19 (1991) 594
75. Gref R., Domb A., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., and Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16 (1995) 215-233
76. Garnett M.C. Targeted drug conjugates: Principles and progress. Adv. Drug Deliv. Rev. 53 (2001) 171-216
77. Scherphof G.L., Velinova M., Kamps J., Donga J., Van der Want H., Kuipers F., Havekes L., and Daemen T. Modulation of pharmacokinetic behavior of liposomes. Adv. Drug Deliv. Rev. 24 (1997) 179-191
78. Rodrigues J.M., Fessi H., Bories C., Puisieux F., and Devissaguet J.P. Primaquine-loaded poly(lactide) nanoparticles: Physicochemical study and acute tolerance in mice. Int. J. Pharm. 126 (1995) 253-260
79. Heurtault B., Legrand P., Mosqueira V., Devissaguet J.P., Barratt G., and Bories C. The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro. Ann. Trop. Med. Parasitol. 95 (2001) 529-533
80. Lück M., Paulke B.R., Schröder W., Blunk T., and Müller R.H. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39 (1998) 478-485
81. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58 (2006) 1532-1555
82. Mosqueira V.C.F., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D., and Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22 (2001) 2967-2979
83. Mosqueira V.C.F., Legrand P., Morgat J.L., Vert M., Mysiakine E., Gref R., Devissaguet J.P., and Barratt G. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: Effects of PEG chain length and density. Pharm. Res. 18 (2001) 1411-1419
84. Mosqueira V.C., Legrand P., and Barratt G. Surface-modified and conventional nanocapsules as novel formulations for parenteral delivery of halofantrine. J. Nanosci. Nanotechnol. 6 (2006) 3193-3202
85. Haynes S.M., Longmuir K.J., Robertson R.T., Baratta J.L., and Waring A.J. Liposomal polyethyleneglycol and polyethyleneglycol-peptide combinations for active targeting to liver in vivo. Drug Deliv. 15 (2008) 207-217
86. Singhal A., and Gupta C.M. Antibody-mediated targeting of liposomes to red cells in vivo. FEBS Lett. 201 (1986) 321-326
87. Agrawal A.K., Singhal A., and Gupta C.M. Functional drug targeting to erythrocytes in vivo using antibody bearing liposomes as drug vehicles. Biochem. Biophys. Res. Commun. 148 (1987) 357-361
88. Chandra S., Agrawal A.K., and Gupta C.M. Chloroquine delivery to erythrocytes in Plasmodium berghei-infected mice using antibody-bearing liposomes as drug vehicles. J. Biosci. 16 (1991) 137-144
89. Peeters P.A.M., Brunink B.G., Eling W.M.C., and Crommelin D.J.A. Therapeutic effect of chloroquine (CQ)-containing immunoliposomes in rats infected with Plasmodium berghei parasitized mouse red blood cells: Comparison with combinations of antibodies and CQ or liposomal CQ. BBA - Biomembranes 981 (1989) 269-276
90. Agrawal A.K., and Gupta C.M. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliv. Rev. 41 (2000) 135-146
91. Robertson R.T., Baratta J.L., Haynes S.M., and Longmuir K.J. Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver. J. Pharm. Sci. 97 (2008) 3257-3273
92. Bangham A.D., Standish M.M., and Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13 (1965) 238-252
93. Gregoriadis G., Leathwood P.D., and Ryman B.E. Enzyme entrapment in liposomes. FEBS Lett. 14 (1971) 95-99
94. Gregoriadis G. Drug entrapment in liposomes: possibilities for chemotherapy. Biochem. Soc. Trans. 2 (1974) 117-119
95. Sponton E., Drouin D., and Delattre J. Design of sterile muramyldipeptide-containing oligolamellar liposomes suitable for i.v. injection. Effect of liposome size and lipid composition on their ability to render peritoneal macrophages antitumoral. Int. J. Pharm. 23 (1985) 299-313
96. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 16 (1998) 307-321
97. Ramaldes G.A., Deverre J.R., Grognet J.M., Puisieux F., and Fattal E. Use of an enzyme immunoassay for the evaluation of entrapment efficiency and in vitro stability in intestinal fluids of liposomal bovine serum albumin. Int. J. Pharm. 143 (1996) 1-11
98. Weingarten C., Moufti A., and Desjeux J.F. Oral ingestion of insulin liposomes: Effects of the administration route. Life Sci. 28 (1981) 2747-2752
99. Laham A., Claperon N., Durussel J.J., Fattal E., Delattre J., Puisieux F., Couvreur P., and Rossignol P. Intracarotidal administration of liposomally-entrapped ATP: Improved efficiency against experimental brain ischemia. Pharmacol. Res. Commun. 20 (1988) 699-705
100. Allison A.C., and Gregoriadis G. Liposomes as immunological adjuvants. Nature 252 (1974) 252
101. Alving C.R., and Richards R.L. Liposomes containing lipid A: A potent nontoxic adjuvant for a human malaria sporozoite vaccine. Immunol. Lett. 25 (1990) 275-279
102. Papahadjopoulos D., and Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog. Clin. Biol. Res. 343 (1990) 85-93
103. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
104. Pirson P., Steiger R.F., and Trouet A. Liposomes in the chemotherapy of experimental murine malaria. Trans. R. Soc. S. Afr. 73 (1979) 347
105. Smith J.E., Pirson P., and Sinden R.E. Studies on the kinetics of uptake and distribution of free and liposome-entrapped primaquine, and of sporozoites by isolated perfused rat liver. Ann. Trop. Med. Parasitol. 77 (1983) 379-386
106. Madden T.D., Harrington P.R., Tai L.C.L., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P.S., Reinish L.W., and Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids 53 (1990) 37-46
107. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., and Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. BBA - Rev. Biomembranes 1331 (1997) 187-211
108. Brossi A., Venugopalan B., Dominguez Gerpe L., Yeh H.J.C., Flippen-Anderson J.L., Buchs P., Luo X.D., Milhous W., and Peters W. Arteether, a new antimalarial drug: Synthesis and antimalarial properties. J. Med. Chem. 31 (1988) 645-650
109. Al-Angary A.A., Al-Meshal M.A., Bayomi M.A., and Khidr S.H. Evaluation of liposomal formulations containing the antimalarial agent, arteether. Int. J. Pharm. 128 (1996) 163-168
110. Bayomi M.A., Al-Angary A.A., Al-Meshal M.A., and Al-Dardiri M.M. In vivo evaluation of arteether liposomes. Int. J. Pharm. 175 (1998) 1-7
111. Gabriels M., and Plaizier-Vercammen J. Physical and chemical evaluation of liposomes, containing artesunate. J. Pharm. Biomed. Anal. 31 (2003) 655-667
112. Pirson P., Steiger R.F., and Trouet A. Primaquine liposomes in the chemotherapy of experimental murine malaria. Ann. Trop. Med. Parasitol. 74 (1980) 383-391
113. Pirson P., Steiger R., and Trouet A. The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochem. Pharmacol. 31 (1982) 3501-3507
114. Peeters P.A.M., De Leest K., Eling W.M.C., and Crommelin D.J.A. Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria. Pharm. Res. 6 (1989) 787-793
115. Arica B., Ozer A.Y., Ercan M.T., and Hincal A.A. Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. J. Microencapsul 12 (1995) 469-485
116. Postma N.S., Hermsen C.C., Zuidema J., and Eling W.M.C. Plasmodium vinckei: Optimization of desferrioxamine B delivery in the treatment of murine malaria. Exp. Parasitol. 89 (1998) 323-330
117. Stensrud G., Sande S.A., Kristensen S., and Smistad G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int. J. Pharm. 198 (2000) 213-228
118. Henriksen I., Vågen S.R., Sande S.A., Smistad G., and Karlsen J. Interactions between liposomes and chitosan II: Effect of selected parameters on aggregation and leakage. Int. J. Pharm. 146 (1997) 193-203
119. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 Suppl. 3 (2002) S56-S64
120. Tyagi R.K., Sharma P.K., Vyas S.P., and Mehta A. Various carrier system(s) mediated genetic vaccination strategies against malaria. Expert Rev. Vaccines 7 (2008) 499-520
121. Richards R.L., Hayre M.D., Hockmeyer W.T., and Alving C.R. Liposomes, lipid A, and aluminium hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect. Immun. 56 (1988) 682-686
122. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., and Alving C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen. Infect. Immun. 66 (1998) 2859-2865
123. Verma J.N., Rao M., Amselem S., Krzych U., Alving C.R., Green S.J., and Wassef N.M. Adjuvant effects of liposomes containing lipid A: Enhancement of liposomal antigen presentation and recruitment of macrophages. Infect. Immun. 60 (1992) 2438-2444
124. Sharma S.K., Gupta C., Dwivedi V., Misra-Bhattacharya S., and Mohammad O. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice. Vaccine 25 (2007) 2103-2111
125. Joshi M., Pathak S., Sharma S., and Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int. J. Pharm. 364 (2008) 119-126
126. Wissing S.A., Kayser O., and Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56 (2004) 1257-1272
127. Dierling A.M., and Cui Z. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int. J. Pharm. 303 (2005) 143-152
128. Singh K.K., and Vingkar S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm. 347 (2008) 136-143
129. Mandawgade S.D., Sharma S., Pathak S., and Patravale V.B. Development of SMEDDS using natural lipophile: Application to beta-Artemether delivery. Int. J. Pharm. 362 (2008) 179-183
130. Joshi M., Pathak S., Sharma S., and Patravale V. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int. J. Pharm. 362 (2008) 172-178
131. Xu T., Zhang N., Nichols H.L., Shi D., and Wen X. Modification of nanostructured materials for biomedical applications. Mater. Sci. Eng. C 27 (2007) 579-594
132. Labhasetwar V.D., and Dorle A.K. Nanoparticles - A colloidal drug delivery system for primaquine and metronidazole. J. Control. Release 12 (1990) 113-119
133. Bhadra D., Bhadra S., and Jain N.K. PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether. J. Drug Deliv. Sci. Technol. 15 (2005) 65-73
134. Bhadra D., Bhadra S., and Jain N.K. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm. Res. 23 (2006) 623-633
135. Bhadra D., Yadav A.K., Bhadra S., and Jain N.K. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 295 (2005) 221-233
136. Brewster M.E., and Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59 (2007) 645-666
137. Wong J.W., and Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gama-cyclodextrins. Int. J. Pharm. 227 (2001) 177-185
138. Crandall I.E., Szarek W.A., Vlahakis J.Z., Xu Y., Vohra R., Sui J., and Kisilevsky R. Sulfated cyclodextrins inhibit the entry of Plasmodium into red blood cells. Implications for malarial therapy. Biochem. Pharmacol. 73 (2007) 632-642
139. Hartell M.G., Hicks R., Bhattacharjee A.K., Koser B.W., Carvalho K., and Van Hamont J.E. Nuclear magnetic resonance and molecular modeling analysis of the interaction of the antimalarial drugs artelinic acid and artesunic acid with beta-cyclodextrin. J. Pharm. Sci. 93 (2004) 2076-2089
140. Onyeji C.O., Omoruyi S.I., and Oladimeji F.A. Dissolution properties and characterization of halofantrine-2-hydroxypropyl-beta-cyclodextrin binary systems. Pharmazie 62 (2007) 858-863
141. Ansari M.T., Iqbal I., and Sunderland V.B. Dihydroartemisinin-cyclodextrin complexation: Solubility and stability. Arch. Pharm. Res. 32 (2009) 155-165
142. Müller R.H., Gohla S., Dingler A., and Schneppe T. Large scale production of solid lipid nanoparticles (SLN™) and nanosuspensions (DissoCubes™). In: Wise D. (Ed). Handbook of Pharmaceutical Controlled Release Technology (2000), Marcel Dekker, New York 359-376
143. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56 (2004) 827-840
144. Chingunpitak J., Puttipipatkhachorn S., Chavalitshewinkoon-Petmitr P., Tozuka Y., Moribe K., and Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev. Ind. Pharm. 34 (2008) 314-322
145. Fessi H., Piusieux F., Devissaguet J.P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989)
146. Couvreur P., Barratt G., Fattal E., Legrand P., and Vauthier C. Nanocapsule technology: A review. Crit. Rev. Ther. Drug 19 (2002) 99-134
147. da Silva Santos N.P., Nascimento S.C., Wanderley M.S.O., Pontes-Filho N.T., da Silva J.F., de Castro C.M.M.B., Pereira E.C., da Silva N.H., Honda N.K., and Santos-Magalhães N.S. Nanoencapsulation of usnic acid: An attempt to improve antitumour activity and reduce hepatotoxicity. Eur. J. Pharm. Biopharm. 64 (2006) 154-160
148. Legrand P., Barratt G., Mosqueira V., Fessi H., and Devissaguet J.P. Polymeric nanocapsules as drug delivery systems: a review. S. T. P. Pharm. Sci. 9 (1999) 411-418
149. Pedroni H.C., Bettoni C.C., Spalding S.M., and Dalla Costa T. Plasmodium berghei: Development of an irreversible experimental malaria model in Wistar rats. Exp. Parasitol. 113 (2006) 193-196
150. Maestrelli F., Mura P., and Alonso M.J. Formulation and characterization of triclosan sub-micron emulsions and nanocapsules. J. Microencapsul 21 (2004) 857-864
151. WHO, Global Health Observatory Map Gallery (2008), http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Malaria_ITHRiskMap.JPG, acessed on 30th June 2009.